AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 132 min read$A

Agilent to buy pathology software maker Proscia for $240 million

Agilent Technologies will acquire Proscia, a private pathology software company, for $240 million in cash plus up to $30 million in performance-based payments. Proscia's software digitizes pathology slides for AI analysis. Agilent aims to boost its pathology business and digital diagnostics capabilities. Proscia generated over $18 million in revenue in the past year. The deal is expected to close in early fiscal 2027.

Original reporting
finance.yahoo.com
Published Oct 13, 2026, 12:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Agilent to buy pathology software maker Proscia for $240 million — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ABullishHigh
01

Why it matters

The acquisition positions Agilent in the fast‑growing AI pathology market, potentially unlocking new revenue streams.

02

Market read

First‑report M&A news with material financial terms, likely to move Agilent's stock.

03

What to watch

The earn‑out component ties future performance to Proscia's milestones, adding execution risk.

Relevance 9/10Novelty 9/10Timing: today

Background

Agilent is a leading provider of laboratory instrumentation seeking to broaden its digital pathology footprint.

Company-level read

Ticker impact

$ABullishHigh confidence
Context

Agilent announced acquisition of private pathology software maker Proscia for $240M cash plus up to $30M performance earn‑out.

Expected impact

upward pressure as investors price in growth opportunity in digital pathology.

Evidence & confidence

Acquisition adds a high‑growth software business and aligns with Agilent's strategic push into AI diagnostics.

Market effects

Sector

Strengthens the life‑sciences diagnostics segment and may spur further M&A activity in AI‑driven pathology.

Regional

Positive for US biotech and diagnostics firms, modest impact on broader market.

Global

Highlights growing convergence of hardware and AI software in healthcare worldwide.

Counterpoint

What could challenge this read

Integration risk and potential overpayment could weigh on Agilent if software adoption lags.

Key entities

  • company
    Agilent Technologies

    US‑listed life‑sciences instrumentation firm (ticker A).

  • company
    Proscia

    Privately held pathology software developer.

Read at source← All news

StoryAgilent to acquire digital pathology firm Proscia for up to $270 million

Also covered by

4 outlets

Related articles

OCT 18
$AHighAI 9/10

Philadelphia's Proscia to Sell to Agilent for Up to $270M

Agilent Technologies (NYSE: A) agreed to acquire Proscia, a digital pathology software company, for up to $270M. The deal includes $240M upfront and $30M in performance-based payments. Proscia's software integrates AI tools and manages digital tissue images, serving over 4,000 labs and 16 top pharmaceutical firms. The acquisition aims to expand Agilent's presence in the $5B pathology market, combining its diagnostic instruments with Proscia's software.

mychesco.com2 min
OCT 18
$AHighAI 9/10

Philadelphia AI Cancer Diagnostics Firm Proscia Acquired for Up to $270M

Agilent Technologies (A) is acquiring Proscia, an AI cancer diagnostics firm, for up to $270M ($240M in cash, $30M in milestones). Proscia's software digitizes tissue samples for AI analysis, used by 4,000 labs and 16 top pharma companies. The deal expands Agilent's presence in digital pathology. Proscia will remain in Philadelphia, with the deal expected to close in early fiscal 2027.

philadelphia.today2 min
OCT 18
$AHighAI 9/10

Agilent Agrees to Buy Proscia for $240M

Agilent Technologies agreed to acquire Proscia for $240M in cash, with up to $30M more tied to performance milestones. Proscia's trailing revenue exceeded $18M. The deal will integrate Proscia's digital pathology software into Agilent's business, expected to close in early fiscal 2027.

quasa.io2 min
OCT 16
$BMBLHighAI 9/10

Deal Dispatch: Ithaca Holdings Buys Bumble for $1.3B, The Knot Acquires Zola, Character.ai Bankruptcy

Bumble (BMBL) agreed to a $1.3B all-cash acquisition by Ithaca Holdings, becoming privately held. IonQ will acquire Elisity in an all-stock deal up to $1.3B. Agilent (A) to buy Proscia for $240M. Workday (WDAY) acquiring C1.ai. Aurora Cannabis exploring alternatives to Curaleaf's bid. Character.ai filed for bankruptcy, Disney to pay $20M for IP. Getty Images plans Chapter 11, going private with Koch backing.

finance.yahoo.com3 min
OCT 14
$AHighAI 9/10

Agilent acquires Proscia in deal worth up to $270m

Agilent (A) will acquire Proscia for up to $270m, including $240m upfront and $30m for performance milestones. The deal aims to enhance Agilent's pathology portfolio with Proscia's digital pathology software, Concentriq Dx, which has FDA clearance. Proscia serves over 4,000 labs and 16 top pharma companies, according to Agilent. The acquisition is expected to close in Agilent's fiscal year 2027.

finance.yahoo.com2 min